Acute Porphyria Drug Database

J07CA02 - Diphtheria-Pertussis-Poliomyelitis-Tetanus
Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the diphtheria-pertussis-poliomyelitis-tetanus vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid and inactivated poliovirus (type 1,2 and 3) (DTP-IPV)
Therapeutic characteristics
The DTP-IPV vaccine is indicated for active immunization against diphtheria, tetanus, pertussis and poliomyelitis both for primary immunization and for following booster doses. It is administered by intramuscular injections.
Metabolism and pharmacokinetics
The DTP-IPV vaccine is not metabolized by the cytochrome P450 system.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Tetravac. (Last edition: 30.06 2014). #1888

Similar drugs
Explore alternative drugs in similar therapeutic classes J07C / J07CA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙